Structural basis of TLR and NLR recognition and signaling
TLR 和 NLR 识别和信号转导的结构基础
基本信息
- 批准号:9204376
- 负责人:
- 金额:$ 61.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-01-01 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAgonistAlpha CellAmino AcidsAnti-Inflammatory AgentsBindingBiochemicalBiological AssayBiophysicsC-terminalCell NucleusCell Surface ReceptorsCell physiologyCellsChromatinClinical TrialsCollaborationsCompetitive BindingComplementComplexCrystallizationCytoplasmDevelopmentDiseaseDrug DesignDrug TargetingExhibitsFamilyFamily memberFishesFlagellinGoalsHumanIRF3 geneImmuneImmunityImmunologic ReceptorsInfectionInflammatoryInnate Immune ResponseInvestigationLeadLengthLeucine-Rich RepeatLigand BindingLigandsLymphocyteMHC Class I GenesMethodsMitochondriaMolecularMucosal ImmunityMusMyelogenousNatural ImmunityNucleic AcidsPatternPharmaceutical PreparationsPlayProcessPropertyProteinsRNARNA BindingRadiationRadiation ProtectionRadioprotectionReceptor ActivationReceptor AggregationRegulationRoleSeriesSignal TransductionSignaling MoleculeSpecificityStructureSystemT cell regulationT-Cell ActivationTBK1 geneTLR1 geneTLR5 geneTLR7 geneTLR8 geneTRAF6 geneTestingTherapeuticToll-like receptorsVaccine AdjuvantX-Ray CrystallographyZebrafishadaptive immunitybasebiophysical propertiesbiophysical techniquescancer therapydesignin vivoleucine receptorleucine-rich repeat proteinmembermicrobialmonocytemouse modelpathogenpromoterpublic health relevancereceptorresponsesensorward
项目摘要
DESCRIPTION (provided by applicant): Innate immunity provides a first line of defense against pathogen- or danger-associated molecular patterns. Among known innate receptors, Toll-like receptors (TLRs) and NOD-like receptors (NLRs) share a common structural motif that consists of multiple leucine-rich repeats (LRRs) with some variability in amino- acid residues and length of each repeat. Structural studies of LRRs of variable lymphocyte receptors (VLRs) in jawless fish have also shown that LRR domains are important in ligand recognition. Thus, the LRRs of TLRs and NLRs are essential for interaction with agonist ligands in order to initiate cellular signaling in innate immunity. Furthermore, when the LRR domain is disengaged from the signaling domains, it can negatively regulate innate immunity, by competitively binding to ligands. Thus, the ultimate goal of this study is to advance understanding of the structure and function of LRRs in TLRs and NLRs in ligand-induced activation and signaling. Structural and biophysical characterization of LRR domains in TLR1/2/3/4/5/6 have been accomplished by several groups, including our own, but major unresolved questions remain concerning how TLR7/8/9 interact with and are regulated by nucleic acid and other ligands in response to microbial pathogens. Compared to TLRs, structural investigation of NLRs has been extremely limited. To date, only one NLR LRR structure, that of NLRX1, has been solved and we have also shown that it directly binds RNA ligands. With our extensive expertise in expression, purification, crystallization and characterization of diverse LRR proteins, we will investigate structural, biophysical and functional properties of LRR domains in TLR7/8/9 and NLRC3/4/5, as well as advance our already productive studies of TLR5 and NLRX1. Such findings will address the structural and functional mechanisms that arise from the specific interactions of TLR7/8/9 and NLRC3/4/5 with their cognate ligands and lead to understanding of receptor activation and regulation in innate immunity. We will capitalize on our previous studies of TLR5 and NLRX1 to answer key questions about their signaling mechanisms and how they might be regulated by outside agents. Collaborations on cellular aspects on these receptors with Drs. Andrei Gudkov, Cynthia Leifer and Jenny Ting and on specialized biophysical approaches with Drs. Andrew Ward and David Baker will complement our biophysical and functional studies as well as stimulate development of agonists and antagonists as therapeutics in compromised immunity or in hyper- inflammatory diseases.
描述(由申请人提供):先天免疫提供了针对病原体或病原体相关分子模式的第一道防线。在已知的先天性受体中,Toll样受体(TLR)和NOD样受体(NLR)共有共同的结构基序,其由多个富含亮氨酸的重复序列(LRR)组成,每个重复序列的氨基酸残基和长度具有一些变异性。无颌鱼可变淋巴细胞受体(VLRs)的LRR结构研究也表明,LRR结构域在配体识别中很重要。因此,TLR和NLR的LRR对于与激动剂配体的相互作用是必需的,以便在先天免疫中启动细胞信号传导。此外,当LRR结构域从信号传导结构域脱离时,它可以通过竞争性结合配体来负调节先天免疫。因此,本研究的最终目标是促进对TLR和NLR中LRR在配体诱导的激活和信号传导中的结构和功能的理解。TLR 1/2/3/4/5/6中LRR结构域的结构和生物物理学表征已经由包括我们自己在内的几个小组完成,但关于TLR 7/8/9如何与核酸和其他配体相互作用并受核酸和其他配体调节以响应微生物病原体的主要未解决问题仍然存在。与TLR相比,NLR的结构研究非常有限。到目前为止,只有一个NLR LRR结构,即NLRX 1,已被解决,我们还表明,它直接结合RNA配体。凭借我们在表达,纯化,结晶和表征各种LRR蛋白方面的广泛专业知识,我们将研究TLR 7/8/9和NLRC 3/4/5中LRR结构域的结构,生物物理和功能特性,以及推进我们已经对TLR 5和NLRX 1的生产性研究。这些发现将解决TLR 7/8/9和NLRC 3/4/5与其同源配体的特异性相互作用所产生的结构和功能机制,并导致对先天免疫中受体激活和调节的理解。我们将利用我们以前对TLR 5和NLRX 1的研究来回答关于它们的信号传导机制以及它们如何被外部因子调节的关键问题。与Andrei Gudkov、Cynthia Leifer和Jenny Ting博士在这些受体的细胞方面的合作以及与Andrew Ward和大卫贝克博士在专门的生物物理方法上的合作将补充我们的生物物理和功能研究,并刺激激动剂和拮抗剂的开发,作为免疫受损或炎症性疾病的治疗剂。
项目成果
期刊论文数量(16)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
T-cell receptor peptide-MHC interactions: biological lessons from structural studies.
T 细胞受体肽-MHC 相互作用:结构研究的生物学教训。
- DOI:10.1016/s0958-1669(98)80004-9
- 发表时间:1998
- 期刊:
- 影响因子:7.7
- 作者:Garcia,KC;Teyton,L
- 通讯作者:Teyton,L
Structure and functional characterization of the RNA-binding element of the NLRX1 innate immune modulator.
- DOI:10.1016/j.immuni.2011.12.018
- 发表时间:2012-03-23
- 期刊:
- 影响因子:32.4
- 作者:Hong M;Yoon SI;Wilson IA
- 通讯作者:Wilson IA
Soluble human TLR2 ectodomain binds diacylglycerol from microbial lipopeptides and glycolipids.
- DOI:10.1177/1753425914524077
- 发表时间:2015-02
- 期刊:
- 影响因子:3.2
- 作者:Jiménez-Dalmaroni MJ;Radcliffe CM;Harvey DJ;Wormald MR;Verdino P;Ainge GD;Larsen DS;Painter GF;Ulevitch R;Beutler B;Rudd PM;Dwek RA;Wilson IA
- 通讯作者:Wilson IA
Crystal structure of an isolated V(alpha) domain of the 2C T-cell receptor.
2C T 细胞受体的分离 V(α) 结构域的晶体结构。
- DOI:10.1006/jmbi.2001.5113
- 发表时间:2001
- 期刊:
- 影响因子:0
- 作者:Rudolph,MG;Huang,M;Teyton,L;Wilson,IA
- 通讯作者:Wilson,IA
Structural basis of TLR5-flagellin recognition and signaling.
- DOI:10.1126/science.1215584
- 发表时间:2012-02-17
- 期刊:
- 影响因子:0
- 作者:Yoon SI;Kurnasov O;Natarajan V;Hong M;Gudkov AV;Osterman AL;Wilson IA
- 通讯作者:Wilson IA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IAN A WILSON其他文献
IAN A WILSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IAN A WILSON', 18)}}的其他基金
High-throughput assays and small-molecule discovery of antiviral candidates targeting influenza hemagglutinin
针对流感血凝素的抗病毒候选药物的高通量测定和小分子发现
- 批准号:
10397532 - 财政年份:2021
- 资助金额:
$ 61.43万 - 项目类别:
High-throughput assays and small-molecule discovery of antiviral candidates targeting influenza hemagglutinin
针对流感血凝素的抗病毒候选药物的高通量测定和小分子发现
- 批准号:
10612773 - 财政年份:2021
- 资助金额:
$ 61.43万 - 项目类别:
PROJECT 2:Structural studies of SOSIP trimers
项目2:SOSIP三聚体的结构研究
- 批准号:
10336287 - 财政年份:2015
- 资助金额:
$ 61.43万 - 项目类别:
PROJECT 2:Structural studies of SOSIP trimers
项目2:SOSIP三聚体的结构研究
- 批准号:
10643721 - 财政年份:2015
- 资助金额:
$ 61.43万 - 项目类别:
Exploiting sites of vulnerability on influenza viruses
利用流感病毒的脆弱点
- 批准号:
9114253 - 财政年份:2015
- 资助金额:
$ 61.43万 - 项目类别:
PROJECT 2:Structural studies of SOSIP trimers
项目2:SOSIP三聚体的结构研究
- 批准号:
10427133 - 财政年份:2015
- 资助金额:
$ 61.43万 - 项目类别:
PROJECT 2:Structural studies of SOSIP trimers
项目2:SOSIP三聚体的结构研究
- 批准号:
10083182 - 财政年份:2015
- 资助金额:
$ 61.43万 - 项目类别:
相似海外基金
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 61.43万 - 项目类别:
Augmenting the Quality and Duration of the Immune Response with a Novel TLR2 Agonist-Aluminum Combination Adjuvant
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10499193 - 财政年份:2021
- 资助金额:
$ 61.43万 - 项目类别:
A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine
一种基于 TLR5 激动剂的新型脊髓灰质炎病毒疫苗佐剂
- 批准号:
9305008 - 财政年份:2016
- 资助金额:
$ 61.43万 - 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
- 批准号:
8054408 - 财政年份:2010
- 资助金额:
$ 61.43万 - 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
- 批准号:
7909550 - 财政年份:2010
- 资助金额:
$ 61.43万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
8126073 - 财政年份:2010
- 资助金额:
$ 61.43万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
7899536 - 财政年份:2009
- 资助金额:
$ 61.43万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7362543 - 财政年份:2007
- 资助金额:
$ 61.43万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7502193 - 财政年份:2007
- 资助金额:
$ 61.43万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7911043 - 财政年份:2007
- 资助金额:
$ 61.43万 - 项目类别:














{{item.name}}会员




